Comparative studies of glatiramer acetate and interferon beta

International MS Journal

Volumn 15, Issue 2, 2008, Pages 39-41

  Goodin, D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO;

CLINICAL TRIAL; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED PRACTICE; EXPANDED DISABILITY STATUS SCALE; FLU LIKE SYNDROME; HUMAN; IMAGE ANALYSIS; INJECTION SITE REACTION; LIVER DYSFUNCTION; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK REDUCTION; SCORING SYSTEM; SHORT COURSE THERAPY; TREATMENT DURATION;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES; TREATMENT OUTCOME;

EID: 51649088205     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (21)

1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicentter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 655-61
2. Paty D, Li D, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a controlled multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 662-7
3. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing - remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45: 1268-76
4. Comi G, Filippi M, Wolinski JS. European/Canadian multicenter, double-blind randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49: 290-7
5. Jacobs LD, Cookfair DL, Rudick RA, et al and the Multiple. Sclerosis Collaborative Research Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39: 285-94
6. Simon JH, Jacobs LD, Campion M, et al and the Multiple Sclerosis Collaborative Research Group. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol. 1998;43: 79-87.
7. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352: 1498-504
8. Li D, Paty D, UBC MS/MRI Analysis Research Group, PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46: 197-206
9. Hartung HP, Gonsette R, Konig N, et al and the MIMS Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25
10. Krapf H, Morrissey SP, Zenker O, et al and the MIMS Study Group. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology. 2005;65: 690-5.
11. Polman C, O'Connor P, Havrdova E, et al. A Randomized, placebo-controlled trial of natalizumab for relasing multiple sclerosis. N Engl J Med 2006;354: 899-910.
12. Goodin DS, Biermann LD, Bohlega S and the International Working Group for Treatment Optimization in MS. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Curr Med Res Opin. 2007;23: 2823-32.
13. Goodin DS, Traboulsee A, Ebers G, et al and the 16-Year Long-Term Follow-up Study Investigators. Relationship between early clinical characteristics and long-term disability outcomes: 16-year follow-up of the pivotal IFNB-1b study in MS (submitted).
14. Coyle PK, Barkhof F, Chang P, et al. The REGARD trial: safety and immunogenicity from a randomized, assessor-blinded trial of interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: (Suppl 2) S270 P232B
15. O'Connor P, Arnason BGW, Comi G, et al. Interferon beta-1b 500 μg, interferon beta-1b 250 μg and glatiramer acetate: primary outcomes of the Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose study. AAN, 2008; Late Breaker presentation S004.
16. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease-modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58: 169-78.
17. Durelli L, Verdun E, Barbero P, et al and the Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359: 1453-60.
18. Barbero P, Bergui M, Versino E, et al and the INCOMIN Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Mult Scler. 2006;12: 72-6.
19. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002;59: 1496-506.
20. Panitch H, Goodin D, Francis G, et al. Benefit of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239: 67-74.
21. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50: 121-127.